

HEALTHCARE MONTHLY

MAY 2022

Our healthcare team architects market-defining outcomes for some of the world's most innovative medical device, life science, diagnostics, healthcare services and pharmaceutical companies

BioTech / Pharma Healthcare Services Life Sciences / Diagnostics Medical Devices

HEADLINE TRANSACTIONS

TARGET

ACOUIROR

ACQUISITION SYNOPSIS





- ArchiMed SAS has reached an agreement to acquire Natus Medical, Inc. (NASDAQ:NTUS)
- · Natus Medical develops, manufactures and markets screening products for the identification and monitoring of common medical disorders
- · ArchiMed is a private equity firm based in France with more than \$4 billion AUM
- · Total Consideration: \$1.2 billion
- Implied Enterprise Value: 2.4x LTM Revenue, 19.2x LTM EBITDA
- Per share price represents a premium of ~29%





- Clayton, Dubilier & Rice, LLC entered into an agreement to acquire Humana Inc.'s Home Hospice and Personal Care Divisions (NYS:HUM
- Humana's Home Hospice and Personal Care Divisions include patient-centered services for hospice, palliative, community and personal care
- Clayton, Dubilier & Rice is a private equity firm with more than \$50 billion AUM
- · Total Consideration: \$2.8 billion in cash
- Implied Enterprise Value: \$3.4 billion, 12x 2022E EBITDA



STONE POINT CAPITAL

- Stone Point Capital LLC entered into a definitive agreement to acquire Tivity Health, Inc. (NASDAQ:TVTY)
- Tivity Health provides health improvement, fitness and social engagement solutions
- Stone Point Capital is a private equity firm with more than \$40 billion AUM
- Total Consideration: \$1.9 billion, including \$1.6 billion in cash
- Implied Enterprise Value: 4.0x LTM Revenue, 12.5x LTM EBITDA
- Per share price represents a premium of ~20%

Bigerd / Phama Sierch / Sierch / Phama Sierch / Phama Sierch / Sie




- GlaxoSmithKline plc (LSE / NYSE:GSK) has reached an agreement to acquire Sierra Oncology, Inc. (NASDAQ:SRRA)
- Sierra Oncology is a late-stage biopharmaceutical company that focuses on targeted therapies for the treatment of rare forms of cancer
- GlaxoSmithKline is a U.K. based company that discovers, researches, develops and markets innovative products in the pharmaceutical, vaccine
 and consumer healthcare industries
- Total Consideration: \$1.9 billion
- Per share price represents a premium of ~39%




HEALTHCARE GROWTH & VALUATION TRENDS


Enterprise Value / LTM Revenue




Enterprise Value / LTM EBITDA



LTM Revenue Growth




LTM Gross and EBITDA Margins*



*EBITDA Margins shown as the gray line.

LTM Stock Price Index





SELECTED HEALTHCARE TRANSACTIONS

Target	Acquiror	BioTech / Pharma Transactions
Antares Pharma, Inc. (NASDAQ:ATRS)	Halozyme Therapeutics, Inc. (NASDAQ:HALO)	Antares Pharma develops and commercializes self-injection pharmaceutical products and technologies, in addition to topical gel-based products Total Consideration: \$952.6 million Implied Enterprise Value: 5.0x LTM Revenue, 29.2x LTM EBITDA Per share price represents a premium of ~49%
Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI)	Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)	Checkmate Pharmaceuticals is a clinical-stage biotechnology company focused on developing proprietary technology to combat cancer through the immune system Total Consideration: \$2271 million in cash Per share price represents a premium of ~336%
SeaStar Medical, Inc.	LMF Acquisition Opportunities, Inc.	SeaStar Medical is a biotechnology company that develops extracorporeal therapies to reduce the consequences of excessive inflammation on vital organs Total Consideration: \$85 million

larget	Acquiror	Life Sci / Diagnostics Transactions
Inform Diagnostics, Inc.	Fulgent Diagnostics, Inc. (NASDAQ:FLGT)	Inform Diagnostics provides subspecialty anatomic pathology services intended to assist clinicians in the pathology, laboratory and data service sectors Total Consideration: \$170 million in cash
Versant Diagnostics	Iron Path Capital	Versant Diagnostics is an independent physician services company focused on anatomic pathology Total Consideration: \$100 million
Specific Diagnostics, Inc.	BioMerieux SA	Specific Diagnostics develops a rapid antimicrobial susceptibility test (AST) system

Selected TM Capital Healthcare Experience









Target Acquiror Medical Device Transactions MD Orthopaedics designs and develops a custom fit bracing system intended to support the dissemination of the treatment for clubfoot Total Consideration: \$8.2 million in cash, \$8.9 million in common shares and \$2.5 million in restricted stock Trelleborg Sealing Chilipse Sealing Chilipse Sealing EirMed designs, engineers, manufactures, assembles

EirMed LLC

Solutions through its subsidiary
Trelleborg AB

EirMed designs, engineers, manufactures, assembles and packages medical devices for biotechnology, cardiovascular, dentistry, diagnostics and other medical markets

GI Supply, Inc.

Laborie Medical
Technologies, Inc.
sponsored by
Patricia Industries

GI Supply manufactures endoscopy and paracentesis products for gastroenterologists, colorectal surgeons and interventional radiologists

TM Capital's Healthcare Industry Contacts



James McLaren Managing Director jmclaren@tmcapital.com 212.809.1414



John Dean Principal jdean@tmcapital.com 404.995.6234



Michael Goldman Managing Director mgoldman@tmcapital.com 212.809.1419



Steve Hunter
Managing Director, Sponsor Covera
shunter@tmcapital.com
404.995.6232



Paul Smolevitz
Managing Director
psmolevitz@tmcapital.com

